


Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Available online at www.sciencedirect.com

Respiratory Investigation

journal homepage: www.elsevier.com/locate/resinv



Respiratory rate index utility in high-flow nasal cannula oxygen therapy in COVID-19 pneumonia; what are the perfect boundaries?



Respiratory Investigation

To the Editor:

We have read with interest the article by Takeshita et al. [1] on the use of the respiratory rate index as a predictor of highflow nasal cannula (HFNC) treatment efficacy in patients with coronavirus disease 2019 (COVID-19). This study confirms the complexity of the prediction of HFNC failure [2]. However, there are some issues, in our opinion, that need to be clarified.

First, the authors described "that respiratory rate (RR) after HFNC treatment was significantly higher in the HFNC failure group than in the HFNC success group, whereas the RR before HFNC treatment did not significantly differ between the two groups." In addition, this difference became statistically significant with treatment; thus, we wonder if this data may have depended on the size of the population.

Second, other factors influencing the RR, and therefore its predictive value and specificity, are not considered in the analysis and discussion: i.e., any pre-existing thoraco-pulmonary alterations affecting respiratory mechanics, associated comorbidities, and the severity of the disease. Therefore, no information regarding the method used to diagnose the presence and degree of respiratory failure and exchange of gas, nor information on the pattern and extent of lung damage due to COVID-19 pneumonia was provided (radiological score - Brixia score) [3].

The degree of patients' alertness or presence of psychomotor agitation before starting therapy with HFNC was not clarified, and whether any sort of procedural sedation was used to favor adaptation to HFNC treatment and their influence on the results.

We believe that the integration of RR with these data provides information with greater predictive power in this setting of patients, who have respiratory insufficiency with a high risk of intubation. Therefore, it is more difficult to use only the respiratory rate as a specific and sensitive predictor of HFNC failure.

REFERENCES

- [1] Takeshita Y, Terada J, Hirasawa Y, Kinoshita T, Tajima H, Koshikawa K, et al. High-flow nasal cannula oxygen therapy in hypoxic patients with COVID-19 pneumonia: a retrospective cohort study confirming the utility of respiratory rate index. Respir Investig 2022;60:146-53. https://doi.org/10. 1016/j.resinv.2021.10.005.
- Prakash J, Bhattacharya PK, Yadav AK, Kumar A, Tudu LC, Prasad K. ROX index as a good predictor of high flow nasal cannula failure in COVID-19 patients with acute hypoxemic respiratory failure: a systematic review and meta-analysis. J Crit Care 2021;66:102-8. https://doi.org/10.1016/j.jcrc.2021.08. 012
- [3] Borghesi A, Golemi S, Scrimieri A, Nicosia C, Zigliani A, Farina D, et al. Chest X-ray versus chest computed tomography for outcome prediction in hospitalized patients with COVID-19 [published online ahead of print, 2022 Jan 26]. Radiol Med 2022:1-4. https://doi.org/10.1007/s11547-022-01456-x.

Mariano Mazza*

Domenica Di Costanzo

U.O.C. Pneumologia Semi-Intensiva COVID, A.O. "Sant' Anna e San Sebastiano", di Rilievo Nazionale e Alta Specializzazione, Via Ferdinando Palasciano, 81100, Caserta, Italy

Antonio M. Esquinas Intensive Care Unit, Hospital Morales Meseguer. Murcia, Spain E-mail address: antmesquinas@gmail.com

*Corresponding author. E-mail addresses: dottmmazza@gmail.com (M. Mazza), domenica.dicostanzo@libero.it (D. Di Costanzo)

Available online 29 March 2022

2212-5345/\$ - see front matter © 2022 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved. https://doi.org/10.1016/j.resinv.2022.02.008

Conflict of Interest

The authors have no conflict of interest to declare.